Consequently, clinical outcomes of apatinib plus PD-1 blockades highlighted the synergistic action for cancer therapy, similar to the previous finding in hepatocellular carcinoma patients [17]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.